Diabetic retinopathy: emerging concepts of current and potential therapy

Area of Science:

• Ophthalmology
• Endocrinology
• Pharmacology

Background:

• Diabetic retinopathy (DR) is a leading cause of irreversible blindness globally.
• DR pathogenesis is complex, with partially understood pathways offering potential therapeutic targets.
• Anti-VEGF medications are the primary current treatment for DR.

Purpose of the Study:

• To provide a comprehensive overview of established and emerging pharmacological treatments for diabetic retinopathy.
• To discuss the mechanisms of action and potential benefits of novel candidate medications for DR.
• To highlight the need for improved and personalized treatment strategies for DR.

Main Methods:

• Review of established treatments: pan-retinal photocoagulation, anti-VEGF therapy, corticosteroid therapy, and surgical management.
• Discussion of mechanisms and prospective benefits of novel pharmacological agents.
• Analysis of current treatment limitations and future research directions.

Main Results:

• Established treatments offer short-term efficacy but are not perfect cures for DR.
• Novel candidate medications show promise, but further research is needed.
• Current management strategies require enhancement for long-term effectiveness and patient-specific care.

Conclusions:

• Pharmacological research must focus on developing sustained-release treatments and new drug delivery systems for DR.
• Identifying new molecular targets within DR pathogenesis is crucial for therapeutic advancement.
• Personalized treatment approaches, considering genetic factors and disease stage, are essential for effective DR management.